It has been shown that inhibiting IL-1β/IL-1R1 axis by anakinra, a recombinant IL-1R1 antagonist approved to treat rheumatoid arthritis, is sufficient to reverse DN pathology in mouse model [14]. The gene discussed is IL1B; the disease is rheumatoid arthritis.